IVA Stock Performance, Insider Transaction and News

IVA - Inventiva S.A. - American Depos

Market Cap	171.15M	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-110.43M	Forward P/E	-	EPS next Y	-	50D Avg Chg	-2.00%
Sales	23.16M	PEG	-	EPS past 5Y	-	200D Avg Chg	-12.00%
Dividend	N/A	Price/Book	3.56	EPS next 5Y	-	52W High Chg	-67.00%
Recommedations	-	Quick Ratio	0.86	Shares Outstanding	52.12M	52W Low Chg	73.00%
Insider Own	-	ROA	-69.19%	Shares Float	14.05M	Beta	0.96
Inst Own	9.33%	ROE	-1,642.76%	Shares Shorted/Prior	77.72K/121.87K	Price	3.85
Gross Margin	95.61%	Profit Margin	-	Avg. Volume	154,414	Target Price	-
Oper. Margin	-288.43%	Earnings Date	-	Volume	20,224	Change	-5.64%

Healthcare | Biotechnology | France

About Inventiva S.A. - American Depos

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Inventiva S.A. - American Depos News

04/03/24	Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F
04/01/24	Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript
02:00 AM	Inventiva announces the nomination of Andre Turenne as Director
03/27/24	Inventiva reports its 2023 full-year results
03/22/24	Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results
03/18/24	Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D
03/13/24	Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D
03/07/24	Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed
02/15/24	Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3
01/24/24	Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
01/10/24	Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank
12/20/23	Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program
12/04/23	Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH
11/21/23	Inventiva reports 2023 Third Quarter Financial Information¹
11/06/23	Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023
10/27/23	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls
03:00 PM	Inventiva reports its 2023 first-half financial results and provides a corporate update
09/20/23	Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea
08/31/23	Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
07/27/23	Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

IVA Chatroom

Quantumup Posted - 5 days ago

BofA #MASH Primer~Sees attractive investment opportunity Says Multifactorial nature of #MASH supports multiple MoAs $MDGL $IVA $VKTX $ETNB AKRO $ALGS IONS SGMT LLY NVO PFE NGM REGN ALNY ARWR GILD ALT 📝's space has heated up, w/ >30 players Ests #MASH mkt = $23B by '35:

Behavioral_Finance Posted - 1 week ago

$IVA #INVENTIVA #MASH #NASH Lani efficacious on restoring liver vascular biology in animal models; clinical data on capillarisation suggest clinical relevance $VKTX $MDGL $NOVO $LLY

Quantumup Posted - 2 weeks ago

Canaccord Genuity raised the PT on $IVA to $20 was $12/Buy: We reiterate our BUY rating on shares of IVA and increase our 12-month PT from $12 to $20. The increase is primarily driven by the adjustment of estimated pricing for lanifibranor. We assume the same WAC pricing for lani as Rezdiffra/resmetirom. We also pushed back the anticipated launch year of Lani in the U.S. market from 2026 to 2027 given the anticipated enrollment completion in 1H24 and the 72-week duration of the study. $mdgl

History101 Posted - 1 month ago

$IVA 445 watching 3/26/2024

Behavioral_Finance Posted - 1 month ago

@polyglot15 $IVA just at the 50-d ma

AnnieBullBucks Posted - 1 month ago

$IVA exited this stock after looking at dilution tracker. I just don’t feel good holding it so not for me right now. I may soon regret it as I’m still bullish it has a nice pipeline and PT but there is boundless opportunity. GLTA

John___wick44 Posted - 1 month ago

$IVA company is worthless

Quantumup Posted - 1 month ago

Evercore ISI⬆️ $MDGL to $405 was $325/OP: Estimates Rezdiffra peak shr of 18% of the F2/3 pts in the US and 12% abroad w/ lower pricing of $30K ex-US. MD feedback has been strong, suggesting usage on top of obesity medicines in up to ~ ½ of pts. Notes patent assumptions. $iva $vktx $akro $ions

AnnieBullBucks Posted - 1 month ago

$IVA data good maybe a bit of sell the news today, imma buying the dip

All_just_a_game Posted - 1 month ago

$IVA Anyone listen to the call? What was said that is sinking this?

John___wick44 Posted - 1 month ago

$IVA easy to see. nothing very impressive about drug. mdgl is way way ahead of them. this is a 2026 story at this ppint. buy at 1.50

Money_never_sleep Posted - 1 month ago

$IVA It's really sad that it ends like this. This is most likely due to debt issues and the lack of future news. I'll come back later. I hope to see a better rise next time

SDBiotechInvestor Posted - 1 month ago

$IVA - Paris always sells the stock overnight. I view it as buying opportunity. If they can get rid of cash overhang it will revalued accordingly.

John___wick44 Posted - 1 month ago

$IVA sell the news was a non event. no one cares and believes there drug is worth anything. selling off and raise coming. see u at 1-2

Hastein Posted - 1 month ago

$IVA Let's go show time

John___wick44 Posted - 1 month ago

$IVA dowm 30 percent today. co is finished for at least a a year and a half. going to all time lows

Behavioral_Finance Posted - 1 month ago

@Lewislloyd no idea. It may take time . IVA completely under radar. $IVA Market cap 1/20 vs $MDGL

Behavioral_Finance Posted - 1 month ago

$IVA Statistically significant reduction in hepatic steatosis in patients treated, -47% and -38% respectively, compared to placebo (0%).

VvapWinner Posted - 1 month ago

$IVA

VvapWinner Posted - 1 month ago

$IVA This is looking good. Should run tomorrow.

swindled_my_broker Posted - 1 month ago

$IVA This doesn't look like anything I care about. GL.

Lewislloyd Posted - 1 month ago

$IVA Wait till tomorrow tho right?

Money_never_sleep Posted - 1 month ago

$IVA

Flowjob Posted - 1 month ago

$IVA they forgot to mention 'Positive' lol Let's see some volume.

SDBiotechInvestor Posted - 1 month ago

$IVA looking forward to CC and analyst commentary tomorrow.

John___wick44 Posted - 1 month ago

$IVA bloodbath tomorrow

SDBiotechInvestor Posted - 1 month ago

$IVA positive data

ap20 Posted - 1 month ago

$IVA Boom!

DiferTrades Posted - 1 month ago

$IVA 🥰Iva

Stocks4thought Posted - 1 month ago

$IVA https://www.youtube.com/watch?v=MKLVmBOOqVU&ab_channel=TheRollingStones

Analyst Ratings

Canaccord Genuity	Buy	Apr 8, 24
HC Wainwright & Co.	Buy	Apr 1, 24
HC Wainwright & Co.	Buy	Mar 20, 24
HC Wainwright & Co.	Buy	Mar 8, 24
Stifel	Buy	Feb 16, 24
HC Wainwright & Co.	Buy	Dec 21, 23
Canaccord Genuity	Buy	Oct 27, 23
Roth MKM	Buy	Sep 21, 23
Guggenheim	Buy	Sep 1, 23